Two classes of sGC agonists are available: stimulators (which increase the enzymatic activity of the reduced form of sGC) and activators (which enhance the activity of the oxidized and apo forms of sCG), which have shown antihypertensive effects in preclinical models of hypertension [75]. This evidence concerns the gene SGCB and Hypertension.